| Literature DB >> 30358940 |
Maryam Bahadori1, Mohammad Motamedifar2, Abdollah Derakhshandeh1, Roya Firouzi1, Azar Motamedi Boroojeni1, Mohsen Alinejad3, Zahra Naziri1.
Abstract
It is common knowledge that fecal microbiota is a primary source of Escherichia coli causing urinary tract infections (UTIs) via the fecal-perineal-urethral route. But, it is still unknown whether E. coli UTI is mainly caused by dominant fecal E. coli isolates (prevalence hypothesis) or the isolates that possess more virulence factors (special pathogenicity hypothesis). In the present study, the urine E. coli isolates of 30 women with UTI were compared with the fecal E. coli isolates of the same patients and healthy control individuals according to the phylogenetic group, virulence genotype, and antibiotic susceptibility pattern. The genetic relatedness of the isolates was specified and compared by pulsed-field gel electrophoresis (PFGE). PFGE analysis showed that most patients (73.3%) had distinct urine isolates which were not similar to any of their fecal isolates. Based on the phylogenetic analysis, most of the urine and fecal isolates of healthy women were assigned to phylogenetic group B2, followed by D. The distribution of phylogenetic groups was significantly different between the urine and the fecal isolates of patients (p < 0.05). The prevalence of fimH and ompT among urine isolates was significantly more than that among fecal isolates. The level of multidrug resistance was higher among urine isolates. Although more in-depth researches are required, the present study could be supported by pathogenicity hypothesis. Furthermore, concerning the antibiotic resistance pattern among uropathogenic E. coli should be highly considered.Entities:
Keywords: zzm321990Escherichia colizzm321990; PFGE; UTI; antibiotic resistance; phylogroup; virulence genes
Mesh:
Substances:
Year: 2018 PMID: 30358940 PMCID: PMC6562127 DOI: 10.1002/mbo3.759
Source DB: PubMed Journal: Microbiologyopen ISSN: 2045-8827 Impact factor: 3.139
Oligonucleotide primers used in the study (Rodriguez‐Siek et al., 2005)
| Targeted genes | Primer sequences (5′–3′) | Amplicon size (bp) |
|---|---|---|
|
| GGACATCCTGTTACAGCGCGCA | 925 |
| TCGCCACCAATCACAGCCGAAC | ||
|
| ATCTTATACTGGATGGGATCATCTTGG | 1,105 |
| GCAGAACGACGTTCTTCATAAGTATC | ||
|
| ATCTAGCCGAAGAAGGAGGC | 559 |
| GGCCAATAAATAATTTCCCGAATC | ||
|
| TATTAATCTTCACAGAGGAG | 930 |
| GGCCAATAAATAATTTCCCGAATC | ||
|
| GACGGCTGTACTGCAGGGTGTGGCG | 328 |
| ATATCCTTTCTGCAGGGATGCAATA | ||
|
| ATTCCTCACAATCAGCGCACTT | 508 |
| ATCAGCAGTACAGCAAACAGGG |
Figure 1Similarity dendrogram and pulsed‐field gel electrophoresis (PFGE) profiles. C: control isolate; S: patient fecal isolate; U: urine isolate, *: two PFGE profiles with 80% similarity, **: a urine and fecal isolate from same patient with 100% similarity
The number (%) of phylogenetic groups among the isolates of three studied groups
| Phylogenetic groups | Source of isolates | Total | ||
|---|---|---|---|---|
| Urine (%) | Patients’ fecal (%) | Controls’ fecal (%) | ||
| A | 13 (14.4) | 29 (32.2 | 5 (16.7) | 47 (22.3) |
| B1 | 6 (6.7) | 11 (12.2) | 3 (10.0) | 20 (9.5) |
| B2 | 53 (58.9) | 22 (24.4) | 12 (40.0) | 87 (41.4) |
| D | 18 (20.0) | 28 (31.1) | 10 (33.3) | 56 (26.9) |
Three isolates were picked from each urine/fecal sample.
The phylogenetic distribution of virulence genes among all studied isolates
| Source of isolates | Total | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Urine | Patients’ fecal | Controls’ fecal | ||||||||||||||
| A | B1 | B2 | D | Total | A | B1 | B2 | D | Total | A | B1 | B2 | D | Total | ||
| Adhesion genes | ||||||||||||||||
|
| 10 (11.0) | 3 (3.3) | 46 (51.1) | 11 (12.2) | 70 (77.7) | 17 (18.8) | 2 (2.2) | 17 (18.8) | 20 (22.2) | 56 (62.2) | 1 (3.33) | 0 (0.0) | 12 (40.0) | 5 (16.6) | 18 (60.0) | 144 (68.5) |
|
| 2 (2.2) | 1 (1.1) | 16 (17.7) | 3 (3.3) | 22 (24.4) | 7 (7.7) | 0 (0.0) | 2 (2.2) | 13 (14.4) | 22 (24.4) | 2 (6.6) | 0 (1.1) | 2 (6.6) | 4 (13.3) | 8 (26.7) | 52 (24.4) |
| Toxin genes | ||||||||||||||||
|
| 0 (0.0) | 0 (0.0) | 3 (3.3) | 0 (0.0) | 3 (3.3) | 0 (0.0) | 1 (1.1) | 1 (1.1) | 0 (0.0) | 2 (2.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (2.3) |
|
| 0 (0.0) | 1 (1.1) | 14 (15.5) | 2 (2.2) | 17 (18.8) | 1 (1.1) | 2 (2.2) | 3 (3.3) | 6 (6.6) | 12 (13.3) | 3 (10.0) | 0 (0.0) | 5 (16.6) | 2 (6.6) | 10 (33.3) | 39 (18.5) |
| Cell protection genes | ||||||||||||||||
|
| 5 (5.5) | 2 (2.2) | 25 (27.7) | 5 (5.5) | 37 (41.1) | 6 (6.6) | 0 (0.0) | 8 (8.8) | 2 (2.2) | 16 (17.7) | 2 (6.6) | 0 (0.0) | 1 (3.3) | 3 (10.0) | 6 (20.0) | 59 (28.0) |
| Other genes | ||||||||||||||||
|
| 2 (2.2) | 1 (1.1) | 21 (23.3) | 11 (12.2) | 35 (38.8) | 1 (1.1) | 1 (1.1) | 5 (5.5) | 18 (20.0) | 25 (27.7) | 0 (0.0) | 0 (0.0) | 1 (3.3) | 5 (16.6) | 6 (20.0) | 66 (31.4) |
The number (%) of resistant isolates to the investigated antibiotics
| Antibiotic | Source of isolates | Total (%) | ||
|---|---|---|---|---|
| Controls’ fecal (%) | Patients’ fecal (%) | Urine (%) | ||
| Ceftazidime | 5 (16.7) | 27 (30.0) | 43 (47.8) | 75 (35.7) |
| Trimethoprim‐sulfamethoxazole | 12 (40.0) | 5 (61.1) | 46 (51.1) | 113 (53.8) |
| Cefixime | 7 (23.3) | 32 (35.6) | 42 (46.7) | 81 (38.6) |
| Gentamicin | 13 (43.3) | 35 (38.9) | 41 (45.6) | 89 (42.4) |
| Ciprofloxacin | 3 (10.0) | 31 (34.4) | 29 (32.2) | 63 (30.0) |
| Ceftriaxone | 9 (30.0) | 30 (33.3) | 34 (37.8) | 73 (34.8) |
| Cefotaxime | 5 (16.7) | 23 (25.6) | 34 (37.8) | 62 (29.5) |
| Cefalexin | 14 (46.7) | 41 (45.6) | 43 (47.8) | 84 (46.7) |
| Nalidixic acid | 10 (33.3) | 34 (37.8) | 45 (50.0) | 89 (42.4) |
| Amikacin | 11 (36.7) | 31 (34.4) | 30 (33.3) | 73 (34.3) |
| Nitrofurantoin | 7 (23.3) | 23 (25.6) | 32 (35.6) | 62 (29.5) |
| Imipenem | 6 (20.0) | 19 (21.1) | 27 (30.0) | 52 (24.8) |